Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that results from the GALAXY-1 trial, which evaluates the Company’s lead drug candidate ganetespib in patients with advanced non-small cell lung adenocarcinoma, will be presented during an oral session at the 15th World Conference on Lung Cancer (WCLC) in Sydney, Australia:
“Randomized Phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma: Results in biomarker sub-groups and all adenocarcinoma patients”
Help employers find you! Check out all the jobs and post your resume.
